Literature DB >> 17534704

High macrophage migration inhibitory factor levels in disseminated intravascular coagulation patients with systemic inflammation.

Satoshi Gando1, Atsushi Sawamura, Mineji Hayakawa, Hirokatsu Hoshino, Nobuhiko Kubota, Jun Nishihira.   

Abstract

To determine the relationship between macrophage migration inhibitory factor (MIF) and disseminated intravascular coagulation (DIC) in patients with systemic inflammatory response syndrome (SIRS) and sepsis, and their relationship to multiple organ dysfunction syndrome (MODS) and prognosis, we conducted a prospective cohort study. Forty-eight patients with SIRS or sepsis were classified as 20 DIC and 28 non-DIC patients. MIF, tumor necrosis factor-alpha (TNF-alpha), soluble fibrin, protein C activity (protein C), and plasminogen activator inhibitor-1 (PAI-1) were all measured within 24 h after the patients met the criteria of SIRS or sepsis (day 0), and on days 1 to 4. The number of SIRS criteria that the patients met and the DIC scores were determined simultaneously. In DIC patients, significantly higher levels of MIF, TNF-alpha, soluble fibrin, PAI-1 were found compared with non-DIC patients. We also found significantly lower protein C levels in the DIC patients than in the non-DIC patients. Significant correlations were found between the peak levels of MIF and soluble fibrin in the DIC patients (rs = 0.496, p < 0.0407). All DIC patients had MODS and also showed a higher number of dysfunctioning organs and a poorer prognosis than the non-DIC patients. A simple logistic regression analysis showed the peak MIF levels and DIC significantly to be related to the patients' death (odds ratio 1.016 and 40.5; p < 0.0409, p < 0.0009, respectively). In conclusion, DIC patients with elevated levels of MIF and TNF-alpha had more organ dysfunctions leading to a poor prognosis in a population of SIRS and sepsis patients. MIF may therefore play a role in the inflammatory and thrombotic processes in DIC patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534704     DOI: 10.1007/s10753-007-9027-1

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  22 in total

Review 1.  Disseminated intravascular coagulation.

Authors:  M Levi; H Ten Cate
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

2.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

3.  Protection from septic shock by neutralization of macrophage migration inhibitory factor.

Authors:  T Calandra; B Echtenacher; D L Roy; J Pugin; C N Metz; L Hültner; D Heumann; D Männel; R Bucala; M P Glauser
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

4.  Growth factor-induced expression of macrophage migration inhibitory factor in osteoblasts: relevance to the plasminogen activator system.

Authors:  S Onodera; K Suzuki; K Kaneda; M Fujinaga; J Nishihira
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

5.  An expanded definition of the adult respiratory distress syndrome.

Authors:  J F Murray; M A Matthay; J M Luce; M R Flick
Journal:  Am Rev Respir Dis       Date:  1988-09

6.  Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness.

Authors:  A Beishuizen; L G Thijs; C Haanen; I Vermes
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

7.  Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis.

Authors:  L E Lehmann; U Novender; S Schroeder; T Pietsch; T von Spiegel; C Putensen; A Hoeft; F Stüber
Journal:  Intensive Care Med       Date:  2001-08       Impact factor: 17.440

8.  Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome.

Authors:  S Gando; J Nishihira; S Kobayashi; Y Morimoto; S Nanzaki; O Kemmotsu
Journal:  Intensive Care Med       Date:  2001-07       Impact factor: 17.440

9.  Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells.

Authors:  Tadamichi Shimizu; Jun Nishihira; Hirokazu Watanabe; Riichiro Abe; Ayumi Honda; Teruo Ishibashi; Hiroshi Shimizu
Journal:  J Biol Chem       Date:  2004-01-21       Impact factor: 5.157

10.  MIF as a glucocorticoid-induced modulator of cytokine production.

Authors:  T Calandra; J Bernhagen; C N Metz; L A Spiegel; M Bacher; T Donnelly; A Cerami; R Bucala
Journal:  Nature       Date:  1995-09-07       Impact factor: 49.962

View more
  9 in total

Review 1.  Macrophage migration inhibitory factor (MIF): a promising biomarker.

Authors:  Gerrit Grieb; Melanie Merk; Jürgen Bernhagen; Richard Bucala
Journal:  Drug News Perspect       Date:  2010-05

2.  VE-cadherin regulates migration inhibitory factor synthesis and release.

Authors:  Ranran Li; Lei Li; Yiyun Liu; Yaoqing Tang; Ruyuan Zhang
Journal:  Inflamm Res       Date:  2019-07-24       Impact factor: 4.575

3.  Elevated levels of macrophage migration inhibitory factor (MIF) in the plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: a relevant role on viral replication.

Authors:  Eduardo G Regis; Victor Barreto-de-Souza; Mariza G Morgado; Marcelo T Bozza; Lin Leng; Richard Bucala; Dumith C Bou-Habib
Journal:  Virology       Date:  2010-01-20       Impact factor: 3.616

4.  Serum macrophage migration inhibitory factor reflects adrenal function in the hypothalamo-pituitary-adrenal axis of septic patients: an observational study.

Authors:  Takashi Miyauchi; Ryoske Tsuruta; Motoki Fujita; Tadashi Kaneko; Shunji Kasaoka; Tsuyoshi Maekawa
Journal:  BMC Infect Dis       Date:  2009-12-21       Impact factor: 3.090

5.  Imbalance between macrophage migration inhibitory factor and cortisol induces multiple organ dysfunction in patients with blunt trauma.

Authors:  Mineji Hayakawa; Kenichi Katabami; Takeshi Wada; Yousuke Minami; Masahiro Sugano; Hidekazu Shimojima; Nobuhiko Kubota; Shinji Uegaki; Atsushi Sawamura; Satoshi Gando
Journal:  Inflammation       Date:  2011-06       Impact factor: 4.092

6.  Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation.

Authors:  Undurti N Das
Journal:  J Inflamm Res       Date:  2010-12-02

7.  Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials.

Authors:  Janos Toldi; David Nemeth; Peter Hegyi; Zsolt Molnar; Margit Solymar; Nelli Farkas; Hussain Alizadeh; Zoltan Rumbus; Eszter Pakai; Andras Garami
Journal:  Sci Rep       Date:  2021-04-13       Impact factor: 4.379

8.  Macrophage migration inhibitory factor is an early marker of severe acute pancreatitis based on the revised Atlanta classification.

Authors:  Dingcheng Shen; Caixi Tang; Shuai Zhu; Gengwen Huang
Journal:  BMC Gastroenterol       Date:  2021-01-22       Impact factor: 3.067

9.  C/EBPδ protects from radiation-induced intestinal injury and sepsis by suppression of inflammatory and nitrosative stress.

Authors:  Sudip Banerjee; Qiang Fu; Sumit K Shah; Stepan B Melnyk; Esta Sterneck; Martin Hauer-Jensen; Snehalata A Pawar
Journal:  Sci Rep       Date:  2019-09-27       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.